Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

macure pharma aps - melphalanhydrochlorid - pulver og solvens til injektions- /infusionsvæske, opløsning - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - melphalan - filmovertrukne tabletter - 2 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

amring farma srl - melphalanhydrochlorid - pulver og solvens til injektions- /infusionsvæske, opløsning - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medac, gesellschaft für klinische spezialpräparate mbh - melphalanhydrochlorid - pulver og solvens til injektions- /infusionsvæske, opløsning - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sun pharmaceutical industries europe bv - melphalanhydrochlorid - pulver og solvens til injektions- /infusionsvæske, opløsning - 50 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multipelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aspen pharma trading limited - melphalan - filmovertrukne tabletter - 2 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - melphalan - filmovertrukne tabletter - 2 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - melphalan - filmovertrukne tabletter - 2 mg